acolyte
发表于 2025-3-23 11:54:45
Tatjana Fabriciusd suicide gene therapy.Provides state-of-the art protocols a.Despite various difficulties, the field of gene therapy, particularly with regard to cancer, has accumulated a tremendous amount of vital pre-clinical and clinical data. "Gene Therapy of Cancer: Methods and Protocols, Second Edition" fully
炼油厂
发表于 2025-3-23 15:36:43
Tatjana Fabricius in the. gene and in the regulation of genes of the retinoblastoma pathway such as . or cyclin .1 occur in a large percentage of tumors and have been well studied. Reintroduction or overexpression of genes suppressing proliferation or promoting apoptosis offers a potential for selective suicide of t
Diaphragm
发表于 2025-3-23 18:34:44
http://reply.papertrans.cn/55/5435/543425/543425_13.png
代理人
发表于 2025-3-23 23:51:14
http://reply.papertrans.cn/55/5435/543425/543425_14.png
头脑冷静
发表于 2025-3-24 02:31:38
http://reply.papertrans.cn/55/5435/543425/543425_15.png
monopoly
发表于 2025-3-24 10:24:25
http://reply.papertrans.cn/55/5435/543425/543425_16.png
textile
发表于 2025-3-24 12:01:27
Tatjana Fabricius for efficient isolation and preparation of dendritic cells (DC) renew the interest in tumor immunotherapy and vaccination, in particular. Engineering of tumor cells with the gene of a particular cytokine is a way of releasing that cytokine at the tumor site. In contrast to bolus administration, it
Cloudburst
发表于 2025-3-24 17:26:28
Tatjana Fabriciusher via specific cell surface receptors such as the selectins, integrins, Cadherins, members of the immunoglobulin superfamily, and of the CD44 superfamily . Surface molecules are necessary for cellular cross-talking and thus have a major impact on gene regulation, immune surveillance, immunologi
linguistics
发表于 2025-3-24 21:28:38
(herceptin) for breast cancer or Iressa (gefitinib) for non-small cell lung cancer among others are limited by lack of efficacy, cellular resistance, and toxicity. Dose escalation and combination therapies designed to overcome resistance and increase efficacy are limited by a narrow therapeutic inde
progestogen
发表于 2025-3-25 00:15:08
978-3-658-28011-6Springer Fachmedien Wiesbaden GmbH, ein Teil von Springer Nature 2019